Clinical Trials Browser

Phase 2 × Not yet recruiting × daratumumab × Clear all

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis

NCT06570915 2025-10-01

T-ALL-2024

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07107529 2025-08-12

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Phase 2 Not yet recruiting

Multiple Myeloma

NCT06931704 2025-04-23

IFM 2024_06

Phase 2 Not yet recruiting

Multiple Myeloma

NCT05527340 2022-09-02

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Phase 2 Not yet recruiting

Multiple Myeloma